The fabry cardiomyopathy: Models for the cardiologist

Annual Review of Medicine

Volumn 62, Issue , 2011, Pages 59-67

  Weidemann, Frank ^a   Niemann, Markus ^a   Warnock, David G ^b   Ertl, Georg ^a   Wanner, Christoph ^a  

^a UNIVERSITY HOSPITAL WÜRZBURG   (Germany)

^b University of Alabama at Birmingham   (United States)

Author keywords

echocardiography; Fabry disease; hypertrophy

Indexed keywords

ALPHA GALACTOSIDASE; GLOBOTRIAOSYLCERAMIDE;

ARTICLE; CARDIOLOGIST; CARDIOMYOPATHY; FABRY DISEASE; HEART LEFT VENTRICLE HYPERTROPHY; HUMAN; LYSOSOME STORAGE DISEASE; PATIENT CARE; PRIORITY JOURNAL; X CHROMOSOME LINKED DISORDER;

ALPHA-GALACTOSIDASE; CARDIOMYOPATHIES; ENZYME REPLACEMENT THERAPY; FABRY DISEASE; FEMALE; HUMANS; MALE; TREATMENT OUTCOME; TRIHEXOSYLCERAMIDES;

EID: 79551599532     PISSN: 00664219     EISSN: None     Source Type: Book Series    
DOI: 10.1146/annurev-med-090910-085119     Document Type: Article

References (39)

1. Harvey W. 2006 (1657). Letter IX, to John Vlackveld (24 April 1657). In The Circulation of the Blood, pp. 200-201. New York: Cosimo Classics
2. Desnick R, Ionnou Y, Eng C. 1995. Fabry disease: alpha galactosidase A deficiency. In The Metabolic and Molecular Bases of Inherited Disease, ed. C Scriver, A Beaudet, W Sly, D Valle, pp. 2741-84. New York: McGraw Hill
3. Linhart A, Kampmann C, Zamorano JL, et al. 2007. Cardiac manifestations of Anderson-Fabry disease: results from the international Fabry outcome survey. Eur. Heart J. 28(10):1228-35
4. Weidemann F, Breunig F, Beer M, et al. 2005. The variation of morphological and functional cardiac manifestation in Fabry disease: potential implications for the time course of the disease. Eur. Heart J. 26(12):1221-27
5. Eng CM, GuffonN,Wilcox WR,etal. 2001. Safety and efficacyof recombinant human alpha-galactosidase A-replacement therapy in Fabry's disease. N. Engl. J. Med. 345(1):9-16
6. Schiffmann R, Kopp JB, Austin HA 3rd, et al. 2001. Enzyme replacement therapy in Fabry disease: a randomized controlled trial. JAMA 285(21):2743-49
7. Weidemann F, Breunig F, Beer M, et al. 2003. Improvement of cardiac function during enzyme replacement therapy in patients with Fabry disease: a prospective strain rate imaging study. Circulation 108(11):1299-301
8. Weidemann F, Niemann M, Breunig F, et al. 2009. Long-term effects of enzyme replacement therapy on Fabry cardiomyopathy: evidence for a better outcome with early treatment. Circulation 119(4):524-29
9. Wanner C. 2007. Fabry disease model: a rational approach to the management of Fabry disease. Clin. Ther. 29(Suppl. A):S2-5
10. Pastores GM, Hughes DA. 2009. To see a world in a grain of sand: elucidating the pathophysiology of Anderson-Fabry disease through investigations of a cellular model. Kidney Int. 75(4):351-53
11. Aerts JM, Groener JE, Kuiper S, et al. 2008. Elevated globotriaosylsphingosine is a hallmark of Fabry disease. Proc. Natl. Acad. Sci. USA 105(8):2812-17
12. Elliott PM, Kindler H, Shah JS, et al. 2006. Coronary microvascular dysfunction in male patients with Anderson-Fabry disease and the effect of treatment with alpha galactosidase A. Heart 92(3):357-60
13. Moon JC, Sachdev B, Elkington AG, et al. 2003. Gadolinium enhanced cardiovascular magnetic resonance in Anderson-Fabry disease. Evidence for a disease specific abnormality of the myocardial interstitium. Eur. Heart J. 24(23):2151-55
14. Sheppard MN, Cane P, Florio R, et al. 2009. A detailed pathologic examination of heart tissue from three older patients with Anderson-Fabry disease on enzyme replacement therapy. Cardiovasc. Pathol. 19:293-301
15. Shah JS, Hughes DA, Sachdev B, et al. 2005. Prevalence and clinical significance of cardiac arrhythmia in Anderson-Fabry disease. Am. J. Cardiol. 96(6):842-46
16. Banikazemi M, Bultas J, Waldek S, et al. 2007. Agalsidase-beta therapy for advanced Fabry disease: a randomized trial. Ann. Intern. Med. 146(2):77-86
17. Beck M. 2009. Agalsidase alfa for the treatment of Fabry disease: new data on clinical efficacy and safety. Expert Opin. Biol. Ther. 9(2):255-61
18. Elleder M, Bradova V, Smid F, et al. 1990. Cardiocyte storage and hypertrophy as a sole manifestation of Fabry's disease. Report on a case simulating hypertrophic non-obstructive cardiomyopathy. Virchows Arch. A Pathol. Anat. Histopathol. 417(5):449-55
19. Barbey F,Brakch N, LinhartA, et al. 2006. Cardiac and vascular hypertrophy inFabry disease: evidence for a new mechanism independent of blood pressure and glycosphingolipid deposition. Arterioscler. Thromb. Vasc. Biol. 26(4):839-44
20. Shen JS, Meng XL, Moore DF, et al. 2008. Globotriaosylceramide induces oxidative stress and up-regulates cell adhesion molecule expressioninFabry disease endothelial cells.Mol. Genet. Metab.95(3):163-68
21. Weidemann F, Wanner C, Breunig F. 2008. Nomen est omen. Eur. J. Echocardiogr. 9(6):831-32
22. WeidemannF,Strotmann JM, NiemannM,et al. 2008. Heart valve involvementinFabry cardiomyopathy. Ultrasound Med. Biol. 35:730-35
23. Linhart A, Elliott PM. 2007. The heart in Anderson-Fabry disease and other lysosomal storage disorders. Heart 93(4):528-35
24. Pieroni M, Chimenti C, Ricci R, et al. 2003. Early detection of Fabry cardiomyopathy by tissue Doppler imaging. Circulation 107(15):1978-84
25. Weidemann F, Strotmann JM, Breunig F, et al. 2008. Misleading terms in Anderson-Fabry disease. Eur. J. Clin. Invest. 38(3):191-96
26. Takenaka T, Teraguchi H, Yoshida A, et al. 2008. Terminal stage cardiac findings in patients with cardiac Fabry disease: an electrocardiographic, echocardiographic, and autopsy study. J. Cardiol. 51(1):50-59
27. Weidemann F, Niemann M, Herrmann S, et al. 2007.Anew echocardiographic approach for the detection of non-ischaemic fibrosis in hypertrophic myocardium. Eur. Heart J. 28(24):3020-26
28. Schaefer RM, Tylki-Szymanska A, Hilz MJ. 2009. Enzyme replacement therapy for Fabry disease: a systematic review of available evidence. Drugs 69(16):2179-205
29. Thurberg BL, Fallon JT, MitchellR, et al. 2009. Cardiac microvascular pathologyinFabry disease: evalua-tionofendomyocardial biopsies before and after enzyme replacement therapy. Circulation 119(19):2561-67
30. Hughes DA, Elliott PM, Shah J, et al. 2008. Effects of enzyme replacement therapy on the cardiomyopathy of Anderson-Fabry disease: a randomised, double-blind, placebo-controlled clinical trial of agalsidase alfa. Heart 94(2):153-58
31. Mehta A, Clarke JT, Giugliani R, et al. 2009. Natural course of Fabry disease: changing pattern of causes of death in FOS-Fabry Outcome Survey. J. Med. Genet. 46(8):548-52
32. Waldek S, Patel MR, Banikazemi M, et al. 2009. Life expectancy and cause of death in males and females with Fabry disease: findings from the Fabry Registry. Genet. Med. 11(11):790-96
33. Close L, Elliott P. 2007. Optimization of concomitant medication in Fabry cardiomyopathy. Acta Paediatr. Suppl. 96(455):81-83
34. Tahir H, Jackson LL, Warnock DG. 2007. Antiproteinuric therapy and Fabry nephropathy: sustained reduction of proteinuria in patients receiving enzyme replacement therapy with agalsidase-beta. J. Am. Soc. Nephrol. 18(9):2609-17
35. Vedder AC, Breunig F, Donker-Koopman WE, et al. 2008. Treatment of Fabry disease with different dosing regimens of agalsidase: effects on antibody formation and GL-3. Mol. Genet. Metab. 94(3):319-25
36. Wilcox WR, Banikazemi M, Guffon N, et al. 2004. Long-term safety and efficacy of enzyme replacement therapy for Fabry disease. Am. J. Hum. Genet. 75(1):65-74
37. Benichou B, Goyal S, Sung C, et al. 2009. A retrospective analysis of the potential impact of IgG antibodies to agalsidase beta on efficacy during enzyme replacement therapy for Fabry disease. Mol. Genet. Metab. 96(1):4-12
38. Vedder AC, Linthorst GE, Houge G, et al. 2007. Treatment of Fabry disease: outcome of a comparative trial with agalsidase alfa or beta at a dose of 0.2 mg/kg. PLoS One 2(7):e598
39. Weidemann F, Sommer C, Duning T, et al. 2009. [Division-related function and organ-related therapy in Fabry's disease. An interdisciplinary challenge]. Med. Klin. (Munich) 104(1):10-19